CorKid (SARS-CoV-2 seroconversion in kids) - 1. Amendment

• Conditions: U07.1; COVID-19, virus identified

• Registration Number: DRKS00024203
• Lead Sponsor: niversitätskinderklinik im St.-Josef Hospital Klinikum der Ruhr-Universität-Bochum

Brief Summary

SARS-CoV-2 infection rates in children and adolescents are often underestimated due to asymptomatic or oligosymptomatic infections. Seroprevalence studies can reveal the magnitude of "silent" infections in this age group and help to assess the risk of infection for children but also their role in spreading the disease. In total, 2045 children and their parents from the Ruhr region were finally included after the exclusion of drop-outs. Seroconversion rates among children of all age groups increased from 0.5% to 8% during the study period and were about three to fourfold higher than the officially registered PCR-based infection rates. Only 41% recalled symptoms of infection; 59% were asymptomatic. In 51% of the infected children, at least one parent also developed SARS-CoV-2 antibodies. Depending on local incidences, the rates of seroconversion rose to different levels during the study period. Although the dynamics of infection within the study cohort mirrors local incidence, the figure of SARS-CoV-2 infections in children and adolescents appears to be high. Reported contact with SARS-CoV-2-infected individuals in the same household carries a high risk of infection.

Detailed Description

Not available

Study Timeline

• Study Start: 2021-02-08
• Results First Posted: 2021-11-12
• Study Completion: 2022-12-31
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

inclusion of children / adolescents with
o positive detection of SARS-CoV-2 (naso- / oropharyngeal test or stool) or
o Detection of antibodies against SARS-CoV-2 or
o Urgent suspicion of a recent COVID-19 infection (e.g. if parents tested positive but the children were not tested)

- signed declaration of consent
- Mothers or other family members (fathers, siblings) of the subjects primarily included (of all ages from 6 months)

Exclusion Criteria

- no consent (from parents) to participate in the study

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
In the group of subjects who are tested positive at the time of inclusion (corona outpatient clinic), a seroconversion rate of 70-80% will be detectable.

Secondary Outcome Measures

Name	Time	Method
In children and adolescents suffering from COVID19 or those who were tested positive, late effects will be detectable in approx. 5% of these cases.